Group had 34 percent fewer new drugs savella patient assistance.

Clear improvement thanks to the grass pollen tabletThe results confirmed the effect of grass pollen tablets: hay fever symptoms by 24 percent lower in the group expressed the drug than in the placebo group. Prof savella patient assistance . Group had 34 percent fewer new drugs. Asthma symptoms decreased by up to 64 percent. The immunological blood tests confirmed the effectiveness of the pills. In general, the grass pollen tablets were well tolerated, apart from frequent itching in the mouth as a temporary side effect. Just like being placed in adults, this immunotherapy with the tablet under the tongue also very promising in children, concludes Prof. Further studies will there see if it. Any long term improvements in allergy For a long time standard hay fever treatment of desensitization / immunotherapy with allergens existed skin was. If it that the grass tablets is a similarly effective long-term effects, seeping in the future can can be injection therapy with sublingual treatment, and now also in children.

'? are proud of this are proud of this announcement, which once again confirms the scientific excellence and talent of Qu bec scientists, 'said Paul L' Archev que, president and CEO by G nome Qu bec? 'These results, the direct result of studies of G be financed? Nome Qu? clearly show the strategic role of genomics in the search for solutions to improve human health. Congratulations to the McGill University and G? nome Qu? bec Innovation Centre team, and. Mainly Alexandre Montpetit who trained a group of CNRS on genotyping data analysis on the Illumina platform the center.

About CEL-SCI Corp.CEL-SCI Corporation be development of products, strengthen the immune system. Being main product Multikine looking statements of a the overall phase III trial in advanced the primary head and neck cancers has ready. CEL-SCI being well as developing a vaccine that for preventing and treating swine flu and any other flu to of his LEAPS technology platforms and awaits in brief end the validation of its state - of-the-art facility Maryland which awaits at utilize, order the aseptic filling for stem cell research Manufactured treatments and other biological products for. The company. Branch offices in Vienna, Virginia, and Baltimore, Maryland - In If in this report are, the words 'intends,''believes,''anticipates'and 'expects'and similar terms are intended to identification forward-looking statements. Such statements involve risks and uncertainty may cause actual results may differ from those projected. Factors that lead to or contribute to such discrepancies include, the inability to clinical results clinical trials, timely development by potential products to be be be safe and effective duplicate, showed the SEC necessary official permits, difficulties in manufacturing any the company potential products the inability to the necessary funds and the risk factors listed from periodically in the CEL-SCI Corp. 's SEC filings, among set to, however does not for his report to Form increased 10 limits - K / A for the fiscal year 30 September 2008. Which Company disclaims any obligation to publicly which result of any revisions of these forward -looking statements that are made events events or circumstances after the date of this report or to reflect the occurrence of unanticipated event.

L. The technology combines a little peptide which activates the immune system, was identified a disease-related protein, such as the H1N1 hemaglutinin molecule specified defined a vaccine that can induces an immune response. L. Every construct of consisting of a T-cell binding ligand which inducing previous causing induce confer protective immunity and antigenic -specific production of antibodies in animal models of has shown be composed. In CEL -SCI L. Swine flu vaccine is to TCBLs. Are three different highly preserved protective epitopes from three essential proteins for all the to all influenza A virus strains Technology is a novel T-cell modulation platform technologies that enables CEL-SCI draft and to synthesize proprietary immunogenic. All illness for which one antigenic sequence of has been identified, such as infectious, parasitic , malignant and autoimmune diseases and allergy are potential therapeutic and preventive stations for the application of LEAPS technology.